| Similar Articles |
|---|
 |
The Motley Fool
July 30, 2004
J. Graham |
Biolase by the Numbers The dental laser company is trying to shore up investor confidence by declaring a dividend and shaking up management, but their poor numbers, among other problems, keep it from being a good buy for now.   |
The Motley Fool
May 9, 2007
Rich Duprey |
BioLase's Dull Quarter The dental laser maker makes good on its promise of a disappointing quarter, but the future may be bright for investors. |
BusinessWeek
December 8, 2003
Gene G. Marcial |
More Dentists Are Drilling With Biolase Biolase makes laser dental drills quieter and less painful. The stock was knocked down because of an accounting restatement, but some pros think it is a good buy. |
The Motley Fool
November 8, 2006
Rich Duprey |
BioLase's Reason to Smile Dental laser maker narrows loss and inks distribution deal to boost sales. The stock is a little rich at its current prices, though. Investors, take note. |
The Motley Fool
April 17, 2007
Rich Duprey |
BioLase Darkens Smiles The dental laser maker warns that quarterly revenues will be dramatically lower. Investors, take note. |
The Motley Fool
July 20, 2004
Rich Duprey |
Lasers Lose Focus Dental-equipment manufacturer Biolase reports flat sales. |
BusinessWeek
November 29, 2004
Gene G. Marcial |
Will More Dentists Ask For Biolase Drills? A management shakeup and a new product at Biolase Technology have rekindled interest in the stock, which has been in a deep funk. |
The Motley Fool
July 30, 2004
Rich Smith |
TransAct Decides Not to Act The company will not buy rival printer maker TPG. Investors would be well advised to monitor the company over the coming quarters |
The Motley Fool
May 9, 2005
Rich Smith |
TransAct-ing Badly This former Hidden Gems pick shows why it's "former." The company announced abysmal results for its first quarter of 2005 and lost 10% of its market cap |
The Motley Fool
April 27, 2005
Charly Travers |
Thanks for the Ride, Transkaryotic Selling was the right move, but it's hard to let go of stocks you like. Transkaryotic has certainly done very well for its shareholders. |
The Motley Fool
October 27, 2004
Rich Smith |
eSpeed Poised to Rise Long dead and buried by Wall Street, eSpeed is poised to rise. |
The Motley Fool
July 26, 2005
Gardner & Mann |
For Shame, Warburg Pincus What transpired as a result of misplaced priorities among these board members who are partners at private equity firm Warburg Pincus is a deal that is substantially underpriced based on Transkaryotic's fundamentals. |
The Motley Fool
August 18, 2004
Jeff Hwang |
Is Applied Materials Losing Momentum? The company posted a strong third quarter, but a less optimistic outlook has its shares near its 52-week low. |
The Motley Fool
September 7, 2005
Rich Smith |
TransAct Prints Its Own Numbers The technology company's PR department "reiterates" an earlier forecast. While $0.06 to $0.08 per diluted share was promised both in yesterday's release and one month ago, the method of calculating that result has morphed over the intervening 33 days. Investors, take note. |
The Motley Fool
March 15, 2007
Rich Duprey |
Biolase's Brighter Sales Figures With a firm financial footing in place, even after its shares have risen 50% in the past three months, Biolase could be an addition to your portfolio worth smiling about. |
The Motley Fool
June 14, 2007
Nathan Parmelee |
Target Releases Arrows Made of Money The retailer has done well by shareholders, and might do even better. |
The Motley Fool
November 8, 2006
Rich Duprey |
BioLase Brightens Smiles: Fool by Numbers The dental laser maker released fiscal third-quarter 2006 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
November 30, 2004
Rich Smith |
Merck Execs Circle the Wagons Shareholder anger is elicited by a filing that Merck made with the Securities and Exchange Commission, announcing that in anticipation of a possible hostile takeover, its executives are taking all possible measures to protect... themselves. |
The Motley Fool
January 10, 2006
Rich Duprey |
Biolase Brightens Outlook The aesthetic laser company expects to be cash flow-neutral on flat revenues. Investors cheer. |
The Motley Fool
July 5, 2005
Bill Mann |
This Merger Deserves Revisiting Transkaryotic agreed to $37 per share from Shire Pharmaceuticals -- but that was before the good news rolled in. These shares are worth 30% more today. The market knows it. |
The Motley Fool
June 3, 2004
Rich Smith |
A Bargain TransAction TransAct Technologies will buy rival receipt-printer maker TPG. |
The Motley Fool
April 28, 2006
Rich Smith |
Foolish Forecast: TransAct Is Back Investors, if the company can keep the cash rolling in while it restructures its business, preventing liquidity concerns, and if sales do improve as forecast by both the analyst and the company, TransAct could well pull out of its tailspin yet. |
The Motley Fool
June 9, 2008
Dan Caplinger |
Solve CEO Conflicts Once and for All Shareholders are willing to put up with all sorts of excesses as long as stock prices are rising. Once the market hits the skids, however, you start hearing a lot more complaints about bad management. Pick companies where management is on your side. |
The Motley Fool
July 25, 2005
Charly Travers |
Transkaryotic Therapies: What's It Worth? U.K.-based Shire Pharmaceuticals has offered to buy Transkaryotic Therapies for $37 a share. Will shareholders be shortchanged? |
The Motley Fool
January 28, 2005
Rich Duprey |
Dentsply Dons a Smile Dental supply company rebounds in fourth quarter with record earnings and profits. |
The Motley Fool
February 17, 2005 |
What's a Dividend? A dividend is a portion of a company's earnings that the firm pays out to its shareholders. |
